1. Ocrevus United States . New drug application, March 2017, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000Lbl.pdf (accessed 29 September 2021).
Google Scholar2. Bar-Or, A, Calabresi, PA, Arnold, D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63(3): 395–400.
Google Scholar | Crossref | Medline3. Rolfes, L, Pawlitzki, M, Pfeuffer, S, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm 2021; 8(5): e1035.
Google Scholar | Crossref | Medline4. Baker, D, Pryce, G, James, LK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Mult Scler Relat Disord 2020; 44: 102279.
Google Scholar | Crossref | Medline5. Barun, B, Gabelic, T, Adamec, I, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult Scler Relat Disord 2020; 48: 102704.
Google Scholar | Crossref | Medline6. Juto, A, Fink, K, Al Nimer, F, et al. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord 2020; 37: 101468.
Google Scholar | Crossref | Medline7. Maarouf, A, Rico, A, Boutiere, C, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e825.
Google Scholar | Crossref | Medline8. Disanto, G, Sacco, R, Bernasconi, E, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol. Epub ahead of print 23 September 2021. DOI: 10.1001/jamaneurol.2021.3609.
Google Scholar | Crossref9. Ellrichmann, G, Bolz, J, Peschke, M, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 2019; 266: 57–67.s
Google Scholar | Crossref | Medline10. Novi, G, Bovis, F, Fabbri, S, et al. Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e845.
Google Scholar | Crossref | Medline